Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies

NCT02013154 is registered in ClinicalTrials.gov with Leap Therapeutics, Inc. as lead sponsor.

NCT NCT02013154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02013154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Lead sponsor
Leap Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 5, 2014
Completion date
January 11, 2021
Enrollment
151 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gastroesophageal junction, esophageal neoplasms, gastric adenocarcinoma, gastroesophageal cancer, squamous cell carcinoma